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Introduction 
Atypical fibroxanthoma (AFX), first described by 
Helwig, represents a low-grade intradermal 
sarcoma of fibrohistiocytic lineage, often situated 
on the head/neck of elderly Caucasian men [1, 2]. 
The clinical prognosis is typically favorable with 
rare reports of metastasis. Although data remain 
scarce, the estimated recurrence and metastatic 
risks in AFX are less than 5% with clear surgical 
margins, whereas the published 
recurrence/metastatic risks of pleomorphic 
dermal sarcomas (PDS) can be as high as 20% [3–
5]. In immunocompetent individuals, the rate of 
AFX metastasis is 2.75% and the recurrence rate 
for wide local excision (WLE) is 7.6% [6, 7]. In 
immunosuppressed individuals, publications have 
described higher rates of recurrence (25%) and 
metastasis (8%), [8]. In these individuals, the 
recurrence rate after WLE can be upwards of 60% 
[8]. 
There is uncertainty as to the exact percentage 
risk for progression of AFX/PDS. Subcutaneous 
Abstract 
Atypical fibroxanthoma (AFX) is a rare cutaneous 
fibrohistiocytic tumor that typically arises on 
chronically sun-damaged skin, such as the head 
and neck, as a nondescript ulcerated papule, 
nodule, or tumor. The clinical prognosis is usually 
favorable and metastasis is rare. Pleomorphic 
dermal sarcoma (PDS), or undifferentiated 
pleomorphic sarcoma, is a recently introduced 
diagnostic moniker for AFX-like tumors with more 
aggressive clinical and histologic features such as 
necrosis and vascular invasion. The exact 
relationship between AFX and PDS has been 
debated. Diagnosis of these tumors is generally 
based on immunohistochemical staining to 
exclude other mimics. A wholly specific marker for 
this tumor does not exist, leading to diagnostic 
ambiguity in certain cases. Herein, we present a 
case of pleomorphic dermal sarcoma in a 53-year-
old man with human immunodeficiency virus that 
displayed patchy S100 staining concerning for 
melanoma upon hospital pathology review. Next-
generation sequencing analysis confirmed a 
mutation pattern consistent with published 
molecular signatures of AFX/PDS. In discussing 
this case, we review the current understanding of 
AFX/PDS and discuss diagnostic pitfalls, as well as 
emphasize on how next-generation sequencing 
techniques might improve accuracy in the 
diagnosis of tumors in the spectrum of AFX/PDS. 
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extension and vascular invasion are well-accepted 
attributes of PDS, diverging from the favorable 
prognosis of AFX [9]. As expected with other non-
melanoma cutaneous malignancies, 
immunosuppressed individuals are more 
vulnerable to disease progression, including 
recurrence and metastasis, which may inflate 
standard risk assessment in AFX cohorts [5, 10]. 
Herein, we describe a polypoid scalp tumor with 
nodal metastasis in the setting of human 
immunodeficiency virus (HIV) and expand on 
pitfalls in the diagnostic workup. We review our 
current understanding of the AFX/PDS spectrum 
and discuss how sequencing technologies can 
contribute to accurate diagnoses. 
 
Case Synopsis 
A 53-year-old man with history of HIV (CD4 count: 
242/millimeter3, viral titer: 242 copies/milliliter), 
non-melanoma skin cancer (NMSC), and anal 
cancer presented to our hospital with a four-
centimeter exophytic, bleeding mass on his scalp, 
enlarging for eight months (Figure 1). 
Histopathologic examination revealed an atypical 
pan-dermal, polypoid proliferation of 
pleomorphic cells with multinucleate forms and 
widespread mitotic figures (Figure 2A, B). CD10 
immunostaining showed strong expression; p63, 
SOX-10, ERG, and desmin were negative, 
consistent with a provisional diagnosis of 
hemorrhagic atypical fibroxanthoma/pleomorphic 
dermal sarcoma (AFX/PDS), (Figure 3). However, 
patchy S100 immunostaining was also observed 
and a diagnosis of melanoma was rendered in the 
hospital laboratory (Figure 2C). S100 staining was 
patchy as opposed to diffuse and co-localized 
consistently with interstitial dendritic cells and 
Schwann cells (Figure 2C). To best classify the 
tumor and bolster the diagnosis, massive parallel 
sequencing analysis was performed. Mutations in  
 
Figure 1. A four-centimeter exophytic, bleeding mass 
enlarging for eight months on the scalp of a 53-year-old 
man. 
 
Figure 2. Skin biopsy from an exophytic, bleeding mass on the scalp of a 53-year-old man. A) Skin biopsy of the enlarging, 
exophytic mass (H&E, 40× panoramic), showing B) an atypical intradermal proliferation of pleomorphic cells with 
multinucleate forms and widespread mitotic figures (square), (H&E, 200×). C) Patchy S100 immunostaining (arrows) of 
interstitial dendritic cells and Schwann cells, 200×. 
B A C 
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PIK3CA, TET2, FAT1, CDKN2A, MDM2, CDK4, 
NOTCH1, SMARCA4, ASXL1, and TP53 were 
identified (Table 1), a mutational profile 
compatible with a molecular signature of 
AFX/PDS. 
Subsequent wide local excision and staging 
workup was pursued to determine the extent of 
disease. Although imaging excluded calvarial 
invasion, positron emission tomography-
computed tomography revealed increased uptake 
in axillary and cervical lymph nodes. Fine needle  
aspiration of cervical lymph nodes confirmed 
nodal metastasis. Given the metastatic 
progression, the patient was diagnosed with 
pleomorphic dermal sarcoma and treated with 
adjuvant pembrolizumab. 
 
Case Discussion 
The World Health Organization Classification of 
Tumors of Soft Tissue and Bone categorizes AFX 
as a dermal-based tumor of uncertain lineage, 
separate from the appellation PDS (also known as 
Table 1. Mutations detected in this patient’s tumor. 
Gene Transcript Coding Variant Protein Change 
Variant Allele 
Fraction 
Clinical 
significance 
PIK3CA NM_006218 c.1624G>A p.E542K 36% Yes 
TET2 NM_001127208 c.3860T>C p.F1287S 18% Yes 
FAT1 NM_005245 c.8928G>A p.W2976* 18% Yes 
CDKN2A_p16 NM_000077 c.171>172delinsTT p.R58* 26% Yes 
CDKN2A_p14 NM_058195 c.214_215delinsTT p.P72L 26% Yes 
NOTCH1 NM_017617 c.4198C>T p.Q1400* 23% Yes 
TP53 NM_000546 c.740_742delinsTTT p.N247_R248delinsIW 11% Yes 
TP53 NM_000546 c.652G>A p.V218M 11% Yes 
SMARCA4 NM_001128844 c.2644G>A p.E882K 13% Yes 
ASXL1 NM_015338 c.1276dupA p.Q428Tfs*10 5% Yes 
TPR NM_003292 c.3428C>T p.S1143F 11% Uncertain 
IKBKE NM_014002 c.1516C>T p.L506F 16% Uncertain 
FBXO11 NM_025133 c.416C>T p.P139L 5% Uncertain 
CASP8 NM_001080125 c.543T>A p.F181L 19% Uncertain 
CTNNB1 NM_001098209 c.1162C>T p.L388F 31% Uncertain 
EPHA3 NM_005233 c.406C>T p.R136* 14% Uncertain 
PDGFRB NM_002609 c.2560G>A p.D854N 19% Uncertain 
EBF1 NM_024007 c.1313C>T p.S438L 13% Uncertain 
MET NM_001127500 c.2224C>T p.P742S 15% Uncertain 
PCM1 NM_006197 c.785C>A p.A262D 46% Uncertain 
PREX2 NM_024870 c.213+1G>A Splice site exon 2 14% Uncertain 
RUNX1T1 NM_001198627 c.1423G>A p.A475T 16% Uncertain 
NOTCH1 NM_017617 c.1181G>T p.G394V 19% Uncertain 
GATA3 NM_001002295 c.401C>T p.P134L 13% Uncertain 
KAT6B NM_012330 c.2671G>A p.E891K 11% Uncertain 
C11orf30 NM_001300942 c.1606C>T p.R536W 58% Uncertain 
KDM5A NM_001042603 c.1409G>A p.W470* 14% Uncertain 
KMT2D NM_003482 c.6749C>T p.P2250L 17% Uncertain 
GLI1 NM_005269 c.365G>A p.G122D 15% Uncertain 
COL1A1 NM_000088 c.1495G>A p.D499N 18% Uncertain 
DOT1L NM_032482 c.3878G>A p.R1293K 13% Uncertain 
MN1 NM_002430 c.1228C>T p.P410S 8% Uncertain 
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undifferentiated pleomorphic sarcoma), which is a 
substitute for “malignant fibrous histiocytoma.” 
Risk factors include ultraviolet radiation, 
immunosuppression, ionized radiation, and skin 
trauma [10]. Historically, the usage of different 
monikers contributed to challenges in defining 
these entities. Limited histopathologic criteria are 
uniformly accepted to differentiate PDS from AFX: 
namely, greater depth of invasion (e.g. 
subcutaneous), lymphovascular or perineural 
invasion, and necrosis [9]. Although the exact 
incidences of AFX and PDS are unknown, it is 
estimated that 0.24% of skin cancers treated with 
Mohs Micrographic Surgery are diagnosed as AFX 
[11]. 
Atypical fibroxanthoma and PDS clinically 
simulate more commonly observed skin cancers, 
generally in older patients. Literature review 
revealed 33 cases of AFX and one case of PDS in 
which incongruent clinical diagnoses were 
rendered prior to histopathological analysis 
(Table 2), [10-35]. Of 26 men and 8 women 
between 11 and 90 years of age, lesions were 
most commonly reported as ulcerated tumors 
(58%), located on the face (42%), scalp (31%), and 
ear (23%), with a median duration of onset of 
three months. The most common pre-operative 
clinical diagnoses included squamous cell 
carcinoma (53%), basal cell carcinoma (45%), and 
melanocytic tumor/melanoma (45%). 
Diagnosis of AFX and PDS is based on 
histopathologic analysis. Histopathology 
generally reveals hyperchromatic, pleomorphic 
spindle cells with multinucleate cells or foamy 
cytoplasmic alteration in close apposition to the 
epidermis. AFX can exhibit disparate microscopic 
patterns with cytological features that encompass 
spindled, clear, or osteoclastic cells, coupled with 
oddities in stromal alteration such as 
keloidal/desmoplastic collagen, hypervascularity, 
regression, and lymphoid aggregates. The 
histological diagnosis of AFX/PDS requires 
immunostaining to arrive at a precise diagnosis, 
mainly to exclude other malignant simulants, 
 
Figure 3. Immunostaining of a biopsy of an exophytic mass on the scalp of a 53-year-old man. A) Immunostaining reveals 
diffuse expression of CD10 in tumor cells (100×). B) Atypical cells are importantly negative for erythroblast transformation-
specific-related gene (ERG), (arrow denotes only positive staining of internal control: blood vessels; 100×). C) Staining is 
negative for SOX10 (triangle denotes only positive staining in internal control: melanocytes; 100×). D) Staining is negative 
for p63 (square denotes positive staining of internal control: basal keratinocytes; 100×). E) Staining is negative for desmin 
(100×). 
 
B C 
A E D 
Volume 25 Number 11| November 2019| 
25(11):5 
 
 
- 5 - 
Dermatology Online Journal  ||  Case Report 
especially when spindled morphology 
predominates. Negative staining with high and 
low molecular weight cytokeratins (CK AE1/AE3, 
CK5/6, CK7), or more efficiently p63 or p40, can 
exclude sarcomatoid squamous cell carcinoma, 
whereas neurocristic markers S100 and SOX10 
can be utilized to exclude desmoplastic 
melanoma (Table 2). The constituent tumor cells 
may be positive for procollagen-1, CD10, CD68, 
CD99, and SMA. Importantly, these markers may 
be positive in other sarcomatoid tumors and are 
only meaningful after negative expression for 
SOX10/S100 or cytokeratins/p63/p40 [36]. 
Desmin and ERG should be considerations to 
exclude leiomyosarcoma and spindled 
angiosarcoma, respectively. The point of pursuing 
a combination of neurocristic markers 
(S100/SOX10) is to exclude rare cases with focal 
expression of either marker that could be 
classified as de-differentiated melanoma or 
sarcomatoid melanoma, which represents a key 
pitfall in the differential diagnosis of AFX. 
Sarcomatoid de-differentiation of melanoma may 
be indistinguishable from PDS, as was recently 
observed in a case of pure-type desmoplastic 
melanoma with dedifferentiation [37]. Rarely, 
AFX/PDS may be difficult to distinguish from 
melanoma and typically this conundrum arises if 
biphenotypic histomorphology (e.g. epithelioid 
and spindled) or biphenotypic immunostaining is 
observed, whereby a diagnosis of de-
differentiated melanoma is posited. Sarcomatoid 
melanoma is a rare occurrence, but melanoma 
may display plasticity with loss of the typical 
immunohistochemical expression profile or show 
limited preservation of S100/SOX10. In instances 
of PDS with patchy S100 staining, as in our 
patient’s case, the diagnosis must be 
differentiated from sarcomatoid dedifferentiated 
melanoma, especially given the difference in 
treatment and prognosis for the two diseases. 
Complicating matters, a reported pitfall in 
AFX/PDS is aberrant expression of Melan-A [38]. 
Surrogate immunostains such as WT1, p75, or 
CD56 may be utilized in ambiguous scenarios, but 
genetic testing provides information that solves 
this dilemma [39]. Our case showed patchy S100 
expression in PDS, attributed to interstitial 
dendritic or Schwann cells that has been similarly 
reported as a pitfall [12]. However, the diagnosis 
of record on resection was “nodular melanoma,” 
sparking concern for de-differentiated melanoma 
[24]. 
To substantiate the diagnosis of AFX/PDS and 
exclude melanoma, next-generation sequencing 
analysis of 400 gene targets was performed at our 
institution. Four studies to date have investigated 
the genomic landscape of AFX and PDS [40–43]. 
Griewank et al. focused exclusively on TERT 
promoter mutations in AFX/PDS [41]. The other 
three articles utilized different sequencing 
approaches to capture the genetic signature of 
AFX/PDS. Our case mirrors the published genetic 
profiles of AFX/PDS, namely with 
mutations/deletions in CDKN2A (encoding P16 
and P14arf), NOTCH1, FAT1, CDK4, MDM2, and 
TP53 (Table 1), [40, 42, 43]. Lai et al. utilized whole 
exome and RNA-sequencing of eight matched 
AFX tumor-normal samples and found co-
deletions of CDKN2A and MTAP, as well as 
mutations in FAT1, COL11A1, CSMD3, and ERBB4. 
Gene expression analysis also showed p53 
pathway down-regulation, which is likely 
precipitated by CDKN2A inactivation [43]. 
Mutations in FAT1, a tumor suppressor, have also 
been found in upwards of 50% of AFX/PDS 
published cases, as well as our case (Table 1), [40]. 
The utility of next-generation sequencing in 
diagnosing AFX/PDS during clinically and 
histopathologically ambiguous scenarios cannot 
be overstated, especially when AFX/PDS may only 
be distinguished from de-differentiated  
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melanoma by genomic signature. Using these 
deep sequencing technologies, it is now accepted 
that AFX/PDS represents a spectrum, which 
provides clarity to a longstanding debate [40]. 
AFX/PDS may be more prevalent and have worse 
clinical outcomes in immunocompromised 
patients [8]. A single-center study reported that 
the incidence of AFX was as high as 78 per 
100,000 renal transplant patients [44]. A review of 
the literature revealed 21 cases of AFX/PDS in 
patients with chronically immunosuppressed 
states (Table 3), [25, 30, 44-56]. These included 
nine cases of transplant immunosuppression, 
seven cases of chronic lymphocytic leukemia, 
three cases of HIV (including our case), and one 
case of mycosis fungoides. An important aspect 
for future study is how immunosuppression alters 
the tumor microenvironment when compared to 
immunocompetent hosts, which subsequently 
impacts tumor progression. 
Conclusion 
Our case emphasizes the potentially aggressive 
nature of AFX/PDS in immunosuppressed 
individuals and highlights the importance of 
understanding the genomic landscape for 
AFX/PDS to overcome immunostaining pitfalls. A 
combination of neurocristic markers should be 
utilized to exclude rare cases with focal expression 
of S100, HMB45, and/or SOX10 that could be 
classified as de-differentiated melanoma or 
sarcomatoid melanoma. Genomic sequencing can 
permit a definitive diagnosis when adequate 
tumor and technology is available. As sequencing 
technologies improve and become more 
accessible, they can be harnessed to better 
characterize malignant tumors when clinical and 
histopathological findings remain equivocal or 
pitfalls stoke diagnostic debate. 
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Table 2. Characteristics of atypical fibroxanthomas and pleomorphic dermal sarcomas with incongruent clinical diagnoses prior to histopathologic analysis published in 
the literature. 
 
N, 
R† A S L Clinical presentation D PMH Clinical diagnosis 
Histological 
diagnosis Immunohistochemical staining 
1 
[12] 
21 F Face 
14-millimeter pruritic, 
enlarging nodule with 
overlying telangiectasias 
3 None Acne AFX 
Pos: None 
Neg: HMB45, Melan-A, FXIIIa, AEP, 
CD31, S100 (limited focally positive 
areas), A1AC, A1AT, NK1, CD68 
2 
[13] 
73 M Face 
15x10-millimeter, deep 
red, slightly domed 
lesion 
1.5 
Basal cell carcinoma, 
squamous cell 
carcinoma 
Amelanotic 
melanoma, Merkel 
cell carcinoma, 
squamous cell 
carcinoma, 
AFX 
Pos: CD68 
Neg: S100, CK AE1/AE3, HMWCK 
3 
[14] 
69 F Face Violaceous nodule 2 Hypertension 
Basal cell 
carcinoma 
AFX ND 
4 
[15] 
75 M Ear 
1.5-centimeter oval-
shaped, exophytic, 
bleeding nodule 
2 ND 
Basal cell 
carcinoma 
AFX 
Pos: CD68, CD163, FXIII, SMA, 
Neg: S100, Melan-A, HMB45 
5 
[15] 
78 M Ear 
1-centimeter juicy red, 
dome-shaped nodule 
12 Basal cell carcinoma 
Basal cell 
carcinoma 
AFX 
Pos: CD68, CD163, FXIII, SMA, 
Neg: S100, Melan-A, HMB45 
6 
[16] 
90 F Face 
15x15-millimeter 
exuberant mass 
ND ND 
Basal cell 
carcinoma 
AFX 
Pos: CD10 
Neg: p63, CK AE1/AE3, S100 
7 
[17] 
90 F Face 
25x15-millimeter 
ulcerated nodule 
4 ND 
Basal cell 
carcinoma 
AFX (clear 
cell variant) 
Pos: Vim, CD68 
Neg: S100, HMB45, FXIIIa, Des, SMA, 
CK AE1/AE3, EMA, CEA, CD45, CD3, 
CD20, CD34 
8 
[18] 
49 M Ear 
1.6-centimeter friable, 
ulcerated nodule with 
underlying beefy red 
skin and hemorrhagic 
crust 
0.7
5 
None Cellulitis 
AFX (clear 
cell variant) 
Pos: CD10, CD68 
Neg: CK AE1/AE3, CK5/6, CK7, p63, 
EMA, S100, Melan-A 
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9 
[19] 
43 M Face 
1-centimeter 
erythematous, firm, 
domed nodule 
8 ND 
Follicular inclusion 
cyst, squamous cell 
carcinoma 
AFX 
Pos: CD10, CD68 
Neg: S100, CK AE1/AE3, CD34 
10 
[20] 
56 M Toe 
1-centimeter tender, 
swollen, and peduncular 
mass 
5 ND 
Keratoacanthoma, 
malignant 
melanoma, 
squamous cell 
carcinoma 
AFX 
Pos: Vim, CD10, CD99, HLA-DR, 
CD68, p53 
Neg: CK AE1/AE3, EMA, HMB45, 
S100, SMA, Des, Myoglobin, MyoD1, 
p63, CD34 
11 
[21] 
86 M Scalp 
9 × 13-millimeter raised 
lesion with overlying 
crust and rolled edges 
2.5 
Squamous cell 
carcinoma 
Keratoacanthoma, 
squamous cell 
carcinoma 
PDS 
Pos: SMA 
Neg: CK AE1/AE3, S100, Des, CD31, 
CD34, p63 
12 
[22] 
ND M ND ND ND ND 
Malignant 
melanoma 
AFX 
(pigmented 
variant) 
Pos: Vim, CD68 (weak) 
Neg: CD34, Des, HMB45, NK1/C3, 
CK AE1/AE3, BerH2, Lyz, A1AC 
13 
[22] 
ND M ND ND ND ND 
Malignant 
melanoma 
AFX 
(pigmented 
variant) 
Pos: Vim, CD68 (weak) 
Neg: S100, CD34, Des, HMB45, 
NK1/C3, CK AE1/AE3, BerH2, Lyz, 
A1AC. 
14 
[23] 
83 F Ear 
Erythematous violaceous 
infiltrative, ulcerated 
onion-like mass with 
hyperkeratotic surface 
and prominent vessels 
ND ND 
Malignant 
melanoma 
(metastatic) 
AFX 
Pos: None 
Neg: S100, CK AE1/AE3, Melan-A, 
p53, CD23, Des 
15 
[22] 
ND M ND ND ND ND Melanocytic tumor 
AFX 
(pigmented 
variant) 
Pos: Vim, CD68 (weak) 
Neg: S100, CD34, Des, HMB45, 
NK1/C3, CK AE1/AE3, BerH2, Lyz, 
A1AC. 
16 
[24] 
11 M Neck 
4-millimeter, crusted, 
pink papule 
3 ND 
Molluscum 
contagiosum, 
pyogenic 
granuloma, nevus 
AFX 
Pos: CD10, CD68, Vim 
Neg: S100, CK AE1/AE3, SMA, CD31 
17 
[25] 
46 F Face 
1.5-centimeter white 
nodule 
ND Renal transplant Nevus AFX 
Pos: Vim, CK AE1/AE3 (weak) 
Neg: CD34, S100 
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18 
[26] 
82 M Ear 
1.5-centimeter split, 
hemispheric, bright red, 
moderately firm, 
bleeding papule 
1.2
5 
Actinic keratoses, 
sebaceous 
hyperplasias 
Pyogenic 
granuloma 
AFX ND 
19 
[27] 
89 M Chest 
2.5-centimeter 
exophytic, yellow, 
ulcerated nodule 
ND ND 
Pyogenic 
granuloma 
AFX 
Pos: CD10, CD99, CD68, and SMA 
Neg: CK AE1/AE3, CAM5.2, S100, 
Melan-A, Des, CDP63, CD31, and 
HHV-8 LNA-1. 
20 
[28] 
81 M Scalp 
5x3-centimeter 
enlarging nodulo-
ulcerative lesion with 
bleeding edges 
90 ND 
Sebaceous 
carcinoma 
AFX 
Pos: Vim, CD68, CD10 
Neg: CK AE1/AE3, EMA, SMA, Des, 
Caldesmon, HMB45 
21 
[29] 
24 F Leg 
2x1.5-centimeter firm, 
brown nodule 
2 ND 
Squamous cell 
carcinoma 
AFX 
Pos: A1AT, CD68 
Neg: CK AE1/AE3, HMB45 
22 
[30] 
44 M Neck 
15-millimeter, tender, 
red, ulcerated nodule 
ND Renal transplant 
Squamous cell 
carcinoma 
AFX 
Pos: Vim, CD99 
Neg: CK AE1/AE3, S100, CD15, 
CD34, CD68, MNF 116, SMA, 
HMB45, Des, PGP 9.5, A1AC, KP1, 
FXIIIa. 
23 
[10] 
58 M Scalp 
20x22-millimeter central 
dome shaped lesion 
ND Solar keratosis 
Squamous cell 
carcinoma 
AFX 
Pos: Actin 
Neg: CAM5.2, CK5/6, CD34, Melan-
A, S100 
24 
[10] 
63 F Face 
6x6-millimeter ulcerated 
lesion 
ND 
Solar keratosis, basal 
cell carcinoma 
Squamous cell 
carcinoma 
AFX 
Pos: CD10 
Neg: CAM 5.2, CD34, Melan-A, S100, 
HMB45, CK AE1/AE3 
25 
[31] 
72 M Leg Ulcerated nodule ND 
Non-melanoma skin 
cancers, warthin 
tumor of parotid 
gland 
Squamous cell 
carcinoma 
AFX (clear 
cell variant) 
Pos: CD10, CD68 
Neg: Tyr, CD34, AR, KRT5, KRT6, 
EMA, CAM5.2, MART-1, SOX10, 
S100, CK AE1/AE3, P40, HMB-45 and 
MSA. 
26 
[10] 
77 M Scalp 
10x8-millimeter 
amelanotic nodule 
ND None 
Squamous cell 
carcinoma 
AFX 
Pos: CD10 
Neg: CAM 5.2, CK 5/6, CD34, Melan-
A, HMB45, CK903 
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27 
[10] 
79 M Face 
10x6-millimeter crusting 
nodule 
ND Solar keratosis 
Squamous cell 
carcinoma 
AFX 
Pos: Actin, CD10 
Neg: CAM 5.2, Melan-A, CK903, 
EMA, Des 
28 
[32] 
80 M Back 
7×5-centimeter ill-
defined, firm and 
violaceous plaque 
3 
Parkinsonism, 
hypertension, 
hyperlipidemia 
Squamous cell 
carcinoma 
AFX (keloidal 
variant) 
Pos: Vim, CD10, SMA, CD68, CD99 
Neg: CK AE1/AE3, S100, HMB45, 
CD31, FXIIIa, Des 
29 
[33] 
81 M Scalp 
11-millimeter solitary, 
domed, red, ulcerated 
nodule 
4 Basal cell carcinoma 
Squamous cell 
carcinoma 
AFX 
Pos: Vim, HHF-35, CD68 
Neg: S100, HMB45, FVIII, CD31, 
CD34, CK AE1/AE3 
30 
[34] 
81 M Face 
3x4-centimeter 
ulcerated nodule 
3 ND 
Squamous cell 
carcinoma 
AFX (clear 
cell variant) 
Pos: Vim, MSA, SMA 
Neg: S100, Des, EMA, CK AE1/AE3, 
CEA 
31 
[35] 
82 M 
Face 
(eye) 
3-centimeter lesion with 
ectropion, exposure 
conjunctivitis, and 
eyelash loss 
1.5 ND 
Squamous cell 
carcinoma 
AFX 
Pos: Vim 
Neg: S100, CK AE1/AE3 
32 
[10] 
82 M Scalp 
5x6-millimeter crusting, 
ulcerated lesion 
ND Solar keratosis 
Squamous cell 
carcinoma 
AFX 
Pos: Vim, CD68 
Neg: CAM 5.2, Melan-A, S100, 
HMB45, CK AE1/AE3, EMA 
33 
[10] 
83 M Scalp 
3x3-millimeter bleeding, 
ulcerated lesion 
ND Basal cell carcinoma 
Squamous cell 
carcinoma 
AFX 
Pos: Vim 
Neg: CAM 5.2, Melan-A, S100, 
HMB45, CK AE1/AE3 
34 
[10] 
89 M Scalp 
8x8-millimeter bleeding, 
ulcerated lesion 
ND None 
Squamous cell 
carcinoma 
AFX 
Pos: CD68 
Neg: CAM5.2, CK5/6, CD34, Melan-
A, HMB45, EMA 
†A: Age (years); AFX: Atypical fibroxanthoma; D: Duration (months); Dx: Diagnosis; F: Female; L: Location; M: Male; N: Number; ND: Not described; Neg: Negative staining for; PDS: 
Pleomorphic dermal sarcoma; PMH: Past medical history; Pos: Positive staining for; R: Reference; S: Sex. 
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Table 3. Characteristics of atypical fibroxanthomas and pleomorphic dermal sarcomas in immunosuppressed patients. 
 
N, R† A G L 
Clinical 
Presentation D PMH Dx 
Associated Skin 
Findings Prognosis 
1 [30] 44 M Neck 
15-millimeter, 
tender, red, 
ulcerated nodule 
ND 
Renal transplant (on azathioprine, 
cyclosporine, and prednisone) 
AFX 
Developed SCCs, 
BCCs, SCC in situ, and 
viral warts 
No recurrence 
2 [25] 46 F Face 
1.5-centimeter white 
nodule that recurred 
following initial 
excision 
ND 
Renal transplant (on azathioprine, 
cyclosporine, and steroids) 
AFX 
Developed Bowen 
disease and SCC 
ND 
3 [44] 57 M Face ND ND 
Renal transplant (on azathioprine 
and prednisone) 
AFX None Recurrence 
4 [45] 65 M Face 
Erythematous, fleshy 
tumor 
ND 
Cardiac transplant (on 
azathioprine, cyclosporine, and 
methylprednisolone) 
AFX 
Developed multiple 
eruptive actinic 
keratoses 
Local recurrence 
with deep 
dermal invasion 
5 [46] 66 M Ear 
1.5-centimeter 
painless cutaneous 
nodule 
6 
Cardiac transplant (on cyclosporine 
and prednisone) 
AFX 
Developed multiple 
actinic keratosis and  
SCCs 
No recurrence  
(18-month 
follow-up) 
6 [47] 66 M 
Upper 
extremity 
ND ND 
Chronic lymphocytic leukemia 
(undergoing chemotherapy during 
AFX diagnosis) 
AFX None 
No recurrence  
(48-month 
follow-up) 
7 [48] 67 ND 
Face (1) 
and scalp 
(2) 
ND ND 
Lung transplant (on acitretin, 
capecitabine, tacrolimus, 
mycophenolate mofetil, 
prednisone) 
AFX, 
PDS 
Developed multiple 
SCCs and BCCs 
Died of graft-
versus-host-
disease 
8 [49] 71 M Scalp 
Exophytic ulcerated 
nodule 
ND 
Human Immunodeficiency Virus 
(CD4 280, undetectable viral load) 
AFX None ND 
9 [50] 75 M 
Face (2) 
and scalp 
(1) 
7-millimeter crusted 
papule; pink 
ulcerated papule  
48 
Cardiac transplant (on 
azathioprine, cyclosporine, and 
prednisone) 
AFX 
Developed multiple 
SCCs 
No recurrence 
10 [51] 76 M Face ND ND 
Chronic lymphocytic leukemia 
(diagnosed 6.8 years earlier) 
AFX None 
No recurrence  
(94-month 
follow-up) 
11 [51] 77 M Scalp ND ND 
Chronic lymphocytic leukemia 
(diagnosed 8.8 years earlier) 
AFX None No recurrence 
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12 [52] 77 F Hand ND ND 
Mycosis fungoides (stage III), 
erythroderma 
AFX None 
Local recurrence 
one year later  
13 [53] 79 M Face 
2-centimeter hard, 
dark red nodule 
ND 
Chronic lymphocytic leukemia 
(concurrently diagnosed) 
AFX None 
Recurrence and 
metastasis 
14 [51] 80 M Scalp ND ND 
Chronic lymphocytic leukemia 
(diagnosed 2.4 years earlier) 
AFX None 
No recurrence  
(162-month 
follow-up) 
15 [51] 84 F Back ND ND 
Chronic lymphocytic leukemia 
(diagnosed 6.7 years earlier) 
AFX None 
No recurrence  
(32-month 
follow-up) 
16 [54] 49 M Back 
9-centimeter skin-
colored, painless, 
mobile, firm nodule 
3 
Acquired Immune Deficiency 
Syndrome (CD4 120, HIV RNA was 
130 copies/mL) 
PDS None 
Metastasized to 
lungs 
17 (CR) 53 M Scalp 
4-centimeter 
exophytic, bleeding 
mass 
18 
Acquired Immune Deficiency 
Syndrome 
PDS None No recurrence 
18 [55] 57 M Scalp 
15-millimeter skin 
tumor that recurred 
following resection 
as multiple nodules 
ND 
Renal transplant (on azathioprine, 
cyclosporine, and prednisolone) 
PDS None 
Patient died 
from recurrence 
and metastasis 
to multiple 
internal organs 
19 [44] 62 M 
Upper 
extremity 
ND ND 
Renal transplant (on azathioprine, 
cyclosporine, and prednisolone) 
PDS 
Developed multiple 
actinic keratosis and 
SCCs 
3 local 
recurrences with 
extension to 
fascia 
20 [44] 70 M 
Lower 
extremity 
2 x 2.5-centimeter 
nodule 
ND 
Renal transplant (on azathioprine, 
cyclosporine, and prednisone) 
PDS None 
No recurrence  
(10-month 
follow-up) 
21 [56] 82 M Scalp 
1.7-centimeter 
erythematous, 
tender, 
hyperkeratotic 
nodule 
ND Chronic lymphocytic leukemia  PDS None 
Local recurrence 
and metastases 
†A: Age (years); AFX: Atypical fibroxanthoma; BCC: Basal cell carcinoma; CR: Current report; D: Duration (months); F: Female; Dx: Diagnosis; L: Location; M: Male; N: Number; ND: Not 
described; PMH: Past medical history; PDS: Pleomorphic dermal sarcoma; R: Reference; S: Sex; SCC: Squamous cell carcinoma. 
